Cytotoxic T-Lymphocytes for EBV-positive Lymphoma, GRALE

Subjects have a type of lymph gland disease called Hodgkin or non-Hodgkin Lymphoma or T/NK-lymphoproliferative disease or severe chronic active Epstein Barr Virus (CAEBV) which has come back, is at risk of coming back, or has not gone away after treatment, including the best treatment investigators know for these diseases. Some of these patients show signs of virus that is called Epstein Barr virus (EBV) that causes mononucleosis or glandular fever ("mono" or the "kissing disease") before or at the time of their diagnosis. EBV is found in the cancer cells of up to half the patients with HD an

Trial Details

NCT ID
NCT01555892
Phase
PHASE1
Sponsor
Baylor College of Medicine
Status
RECRUITING
Cancer Type
Lymphoma
Interventions
  • EBV-specific T cells: A
  • EBV-specific T cells: B
Locations (sample)
  • Houston, Texas, United States|29.76328,-95.36327
  • Houston, Texas, United States|29.76328,-95.36327
  • Houston, Texas, United States|29.76328,-95.36327

Key Eligibility Criteria

  • Any patient, regardless of age or sex, with EBV-positive Hodgkin's or non-Hodgkin's Lymphoma, (regardless of the histological subtype) or EBV (asso…
  • EBV positive tumor (can be pending at this time)
  • Weighs at least 12kg
  • Informed consent explained to, understood by and signed by patient/guardian. Patient/guardian given copy of informed consent.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lymphoma Trials on Trialify →